Cancer screening is evolving, and a Singapore primary care group is now urging patients to understand where emerging blood-based tests fit alongside proven methods. The conversation around early detection is shifting, and clinics are beginning to position newer tools as potential complements to, not replacements for, the screenings that already save lives.
SINGAPORE – Keystone Clinic & Surgery is drawing attention to Multi-Cancer Early Detection (MCED) testing as an option that could sit alongside established cancer screening approaches. As a health screening clinic offering primary and preventive care in Singapore, the practice aims to guide patients on where these newer technologies fit within routine, evidence-based medicine.
The clinic also provides nationally recommended preventive services for eligible patients, including Healthier SG Screening. These programmes are supported through CHAS subsidies, and patients enrolled under Healthier SG may qualify for additional copayment waivers. However, MCED testing remains separate from these national programmes and is not currently part of Singapore’s official cancer screening framework.
A Blood-Based Approach to Screening for Multiple Cancers
MCED tests are often described as liquid biopsy tests. Rather than taking tissue directly from a suspected tumour, they examine a blood sample for biological signals that may point to cancer. These signals can include circulating tumour DNA, cell-free DNA patterns, and other cancer-related markers found in the bloodstream.
For patients, the experience mirrors a standard blood draw. A sample is taken and sent to a lab for analysis. Depending on the platform used, a single blood draw can screen for signals associated with dozens of cancer types—some MCED platforms are designed to look for markers linked to 50 or more cancers.
Yet an MCED test does not confirm a cancer diagnosis. If a signal is detected, additional clinical work is required, which may involve imaging, specialist consultations, and, where appropriate, a tissue biopsy to confirm the finding.
Supporting, Not Replacing, Established Screening
Keystone Clinic & Surgery stresses that MCED testing should be viewed as an additional screening tool, not a substitute for the screenings already recommended by health authorities.
The National Cancer Centre Singapore (NCCS) has similarly advised that MCED tests do not replace recommended screenings such as mammograms for breast cancer, Pap smears for cervical cancer, or colonoscopies for colorectal cancer. These established tests continue to serve specific roles in screening defined populations and cancer types.
This distinction matters because MCED tests can return false-positive and false-negative results. Detection rates vary by cancer type and stage, and early tumours may shed only small amounts of circulating tumour DNA into the blood. Any result must therefore be interpreted within the broader context of a patient’s overall health and existing screening history.
“Multi-Cancer Early Detection (MCED) is an emerging technology which could change our intervention methods from reactive to proactive. These tests can further enhance cancer detection by supplementing the other nationally recommended screening tests,” a spokesperson for Keystone Clinic & Surgery said.
Research Continues in Singapore and Overseas
Global interest in MCED technology is rising, but researchers are still determining how these tests should be integrated into routine screening and whether they ultimately improve long-term population health outcomes.
In Singapore, NCCS has announced a clinical study involving 1,000 individuals at higher risk of cancer due to genetic factors or pre-cancerous conditions. The study, slated for the second half of 2026, aims to assess whether MCED tests can detect early-stage cancers in participants and to monitor their longer-term outcomes.
NCCS has also called attention to the need for evidence involving Asian populations. Much of the existing research has been conducted in Western cohorts, and differences in cancer epidemiology and genetic backgrounds could influence how test performance translates across populations.
The US National Cancer Institute likewise describes multi-cancer detection testing as an area of ongoing research. These tests measure biological signals that cancer cells may release into blood or other body fluids, but abnormal results still require further investigation before a cancer diagnosis can be made.
Placing MCED Within a Wider Early Detection Strategy
For primary care clinics, MCED testing introduces another factor into conversations about cancer risk and preventive health. Screening decisions may depend on age, personal medical history, family history, lifestyle factors, symptoms, and eligibility for established programmes.
The role of medical consultation is therefore key in helping patients understand what an MCED result can and cannot reveal. A negative result does not eliminate the possibility of cancer, while a positive signal does not, on its own, establish a diagnosis.
Keystone Clinic & Surgery encourages patients to discuss cancer screening in light of their individual health and risk profile. This includes staying current with nationally recommended screenings and talking with a doctor about newer technologies, their intended use, limitations, and potential follow-up steps.
About Keystone Clinic & Surgery
Keystone Clinic & Surgery is a primary care medical group in Singapore offering services such as acute and chronic care, vaccinations, health screening, women’s and men’s health services, and selected minor surgical procedures. Its clinics also participate in government healthcare schemes, including CHAS and Healthier SG.
Our Clinic
Upper Boon Keng
Block 18 Upper Boon Keng Road #01-1157 Singapore 380018
Main line: +65 6222 2314
WhatsApp: +65 8077 3901
Email: operations5@keystonemedical.com.sg
Website: https://keystonemedical.com.sg/
Keystone Clinic & Surgery Enquiries
Keystone Clinic & Surgery
+65 8339 3400
Why it matters: As MCED technology advances, patients face new choices about how to approach cancer screening beyond the standard national programmes. Understanding the limitations and proper role of these tests—alongside proven methods like mammograms and colonoscopies—will be critical for making informed preventive health decisions in the years ahead.
